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Background. The use of non-vitamin K antagonist oral anticoagulants (NOACs) for stroke prophylaxis in atrial fibrillation (AF) is increasing rapidly. We compared characteristics of AF patients initiated on NOACs versus vitamin K antagonists (VKAs).
Methods. Using Danish nationwide registry data, we identified AF patients initiating either a VKA or a NOAC from 22 August 2011 until 30 September 2016. We compared patient characteristics including age, gender, comorbidities, concomitant pharmacotherapy and CHA 2 DS 2 -VASc and HAS-BLED scores in patients initiated on a VKA, dabigatran, rivaroxaban or apixaban. Differences were examined using multivariable logistic regression models.
Results. The study population comprised 51 981 AF patients of whom 19 989 (38.5%) were initiated on a VKA, 13 242 (25.5%) on dabigatran, 8475 (16.3%) on rivaroxaban and 10 275 (19.8%) on apixaban. Those patients initiated on apixaban had higher mean AE SD CHA 2 DS 2 -VASc scores than those initiated on a VKA (3.1 AE 1.6 vs. 2.9 AE 1.6). Those initiated on dabigatran had lower mean CHA 2 DS 2 -VASc scores (2.7 AE 1.6) than all other groups. Patients with a history of a prior stroke were significantly more likely to be initiated on a NOAC compared with a VKA [odds ratio (OR) 1.35, 95% confidence interval (CI) 1.28-1.43]. By contrast, patients with a history of myocardial infarction were less likely to be initiated on a NOAC compared with a VKA (OR 0.72, 95% CI 0.67-0.77).
Introduction
Atrial fibrillation (AF) is associated with an increased risk of stroke and transient ischaemic attack (TIA) [1] , and oral anticoagulant (OAC) therapy reduces this risk by 62%. Until 2011, vitamin K antagonists (VKAs) were the only available OAC therapy for stroke prophylaxis for AF patients in Denmark [2] . Several food and drug interactions are associated with VKAs, and frequent dose adjustment and monitoring of the international normalized ratio (INR) are required [3] . Significant underuse of VKAs in western European countries before 2011, reaching treatment rates of only 15-50%, has been reported [4, 5] . Since 2011, several non-vitamin K antagonist oral anticoagulants (NOACs) have been introduced to the market for stroke prophylaxis in patients with nonvalvular AF. These NOACs are now recommended as the first drug of choice as an alternative or in preference to warfarin in the AHA/ACC/HRS and the ESC guidelines for AF management, respectively [6, 7] . These drugs do not require INR monitoring or frequent dose adjustment and are associated with fewer food and drug interactions than VKAs [8] [9] [10] . Since the introduction of the NOACs for AF in Denmark (dabigatran on 22 August 2011, rivaroxaban on 6 February 2012 and apixaban on 10 December 2012), a rapid increase in their use has been reported [11, 12] .
The implementation of NOACs with regard to patient characteristics and whether these differ across patients treated with different types of anticoagulation remain unclear. In particular, a comparison of all NOACs with VKAs for stroke prophylaxis is lacking. Using nationwide data from a real world setting with complete patient inclusion from the introduction of the NOACs in Denmark and with available data until September 2016, we aimed to compare characteristics in AF patients initiated on dabigatran, rivaroxaban and apixaban versus VKAs to evaluate the use of these agents in Denmark for stroke prophylaxis.
Methods

Data sources and the Danish healthcare system
In Denmark, there is a comprehensive, uniform, state-run healthcare system, which is paid for through taxation. The patient must pay for medication outside hospital admissions, but a nationwide scheme ensures subsidy for prescribed medication. In Denmark, the guidelines for stroke prophylaxis in AF patients are equal to the ESC guidelines. Furthermore, there were no restrictions on the use of NOACs during the period investigated in this study.
All Danish citizens have a unique personal identification code. Using this code, data were crosslinked on an individual level from three nationwide registries. The Danish Civil Registration system holds complete data regarding gender, date of birth and death. The Danish National Patient Registry includes discharge diagnosis codes from all hospital contacts (inpatient and outpatient). The Danish National Prescription Registry includes complete and individual data on all fulfilled prescriptions in Denmark.
Patient selection
Patients diagnosed with AF at Danish hospitals and outpatient clinics from 1977 were identified. The study population comprised patients who were OAC na€ ıve until the beginning of the study period (22 August 2011) and initiated on VKAs, dabigatran, rivaroxaban or apixaban for the first time during the period from 22 August 2011 to 30 September 2016. AF was defined as a diagnosis of AF or atrial flutter (diagnosis codes are shown in Table S1 ). The diagnosis of AF has been validated in the Danish registries with a positive predictive value of 99% [13] . Patients initiated on an OAC prior to the diagnosis of AF, <30 or >100 years of age, with valvular AF, venous thromboembolism up to 6 months before OAC initiation, hip or knee arthroplastic surgery within 5 weeks prior to OAC initiation and those initiated on more than one OAC on the same date were excluded.
Study covariates
In this study, the characteristics of interest included gender, age, CHA 2 DS 2 -VASc [heart failure, hypertension, age 65-74 years, age ≥75 years (2 points), diabetes mellitus, stroke/TIA/systemic embolism (2 points), vascular disease, sex category (female)] and HAS-BLED [hypertension, abnormal renal/liver function, history of stroke, history of bleeding, INR (excluded due to missing data), age >65 years, use of drug predisposing to bleeding (antiplatelet or nonsteroidal inflammatory agents) or alcohol abuse] scores, comorbidities including stroke, myocardial infarction, peripheral artery disease, heart failure, chronic kidney disease, prior bleeding, alcohol abuse, hypertension and diabetes and concomitant pharmacotherapy including dipyridamole, antiadrenergic agents, non-loop diuretics, beta-blockers, calcium channel blockers, renin-angiotensin system inhibitors, loop diuretics, digoxin and amiodarone. Diagnosis codes and Anatomical Therapeutic Chemical classification system codes are shown in Table S1 .
Statistical analysis
Baseline characteristics are presented according to type of OAC. Characteristics were compared using the chi-squared test for categorical variables and Kruskal-Wallis test for continuous variables. The calculation of CHA 2 DS 2 -VASc score has been described previously [14] . Using multivariable logistic regression analysis, we estimated the odds ratio (OR) with 95% confidence interval (CI) of being initiated on dabigatran, rivaroxaban or apixaban compared with VKAs according to different patient characteristics. In a subanalysis, we divided time into three periods according to the introduction of dabigatran, rivaroxaban and apixaban, respectively. All analyses were adjusted for calendar year and for all the variables included in each model. A P-value <0.05 was considered statistically significant. All statistical analyses were performed using SAS statistical software version 9.4 and figures were created in RStudio.
Results
Study population
The study population comprised 51 981 AF patients initiated on OAC therapy from 22 August 2011 until 30 September 2016. Of these patients, 19 989 (38.5%) were initiated on a VKA (warfarin in 98%), 13 242 (25.5%) on dabigatran, 8475 (16.3%) on rivaroxaban and 10 275 (19.8%) on apixaban. The median time from AF diagnosis to OAC initiation was 11 days [interquartile range (IQR) 4-279 days]. Figure 1 shows the selection of patients. Baseline characteristics are shown in Table 1 .
Age and gender
Patients initiated on dabigatran were younger (median age 71 years, IQR 65-80) than those initiated on VKAs (median age 73 years, IQR 65-80), whereas those initiated on either rivaroxaban or apixaban were older (median age 74 years, IQR 67-82, and median age 76 years, IQR 68-84, respectively) than those initiated on VKAs (P < 0.01). More female patients were initiated on dabigatran (44.9%), rivaroxaban (48.5%) or apixaban (49.7%) compared with VKAs (42.9%) (P < 0.01) ( Table 1) .
CHA 2 DS 2 -VASc and HAS-BLED scores
Patients initiated on dabigatran had a lower mean AE SD CHA 2 DS 2 -VASc score (2.7 AE 1.6) than patients initiated on VKAs (2.9 AE 1.6) whereas those initiated on rivaroxaban or apixaban had the same or a higher mean CHA 2 DS 2 -VASc score (2.9 AE 1.6 and 3.1 AE 1.6, respectively; P < 0.01) ( Table 1 ). Similar patterns in the distribution of CHA 2 DS 2 -VASc scores at initiation of OAC treatment according to type of OAC are shown in Fig. 2 . The same tendency with regard to the OR for initiation of dabigatran, rivaroxaban or apixaban according to CHA 2 DS 2 -VASc score compared with initiation of VKAs is also depicted in Fig. 3 . Patients with a CHA 2 DS 2 -VASc score of 3-8 had significantly lower odds of being initiated on dabigatran, patients with a CHA 2 DS 2 -VASc score of 2-8 had significantly increased odds of being initiated on rivaroxaban, and those with a CHA 2 DS 2 -VASc score of 1-8 had significantly increased odds of being initiated on apixaban compared with VKAs. Figure S2 shows ORs with 95% CIs for initiation of a NOAC according to CHA 2 DS 2 -VASc score compared with initiation of VKAs.
Patients initiated on dabigatran and rivaroxaban had lower mean AE SD HAS-BLED scores (2.0 AE 1.2 and 2.1 AE 2.1, respectively) than patients initiated on a VKA (2.2 AE 1.2); those initiated on apixaban had the same mean HAS-BLED scores (2.2 AE 1.2) ( Table 1) . Patients initiating a NOAC / A. Gundlund et al.
Comorbidities and concomitant pharmacotherapy
In general, patients initiated on a NOAC experienced fewer comorbidities and received less concomitant pharmacotherapy than patients initiated on a VKA (Table 1 ). An exception was patients with a history of stroke. Overall, 13.9% of patients initiated on VKAs had previously been diagnosed with stroke compared with 15.2%, 14.6% and 17.2% of patients initiated on dabigatran, 
Comorbidities, n (%) rivaroxaban and apixaban, respectively (Table 1) .
Patients with a previous myocardial infarction or chronic kidney disease at initiation of OAC treatment were associated with significantly lower odds of being initiated on dabigatran, rivaroxaban or apixaban compared with a VKA whereas patients with a prior stroke had significantly increased odds of being initiated on one of these NOACs (Fig. 4) . Patients with heart failure had significantly lower odds of initiation of either dabigatran or rivaroxaban compared with a VKA, whereas there were no differences with regard to initiation of apixaban and a VKA. We found no differences in odds of initiation of dabigatran, rivaroxaban or apixaban compared with VKAs in those with a previous bleeding event, but a subanalysis showed that patients with a prior intracranial haemorrhage were more likely to be initiated on apixaban compared with a VKA (OR 1.42, 95% CI 1.09-1.86). Further, patients who had previously suffered from gastrointestinal bleeding were less likely to be initiated on rivaroxaban compared with a VKA (OR 0.84, 95% CI 0.73-0.97). Figure S3 shows ORs with 95% CIs for initiation of one of the NOACs according to comorbidities and concomitant pharmacotherapy compared with initiation of a VKA.
Time trends
When time was divided into three periods (11 August 2011 to 5 February 2012, 6 February 2012 to 9 December 2012 and 10 December 2012 to 30 September 2016), small differences were seen with regard to treatment with dabigatran (data not shown). However, trends observed during the last time period were similar to those illustrated in the main analysis (Figs 3 and 4) .
Dosage of NOACs
Amongst patients initiated on a NOAC, some received a restricted dosage compared to the general recommended dosage for stroke prophylaxis in AF patients: 5343 (40.3%) patients initiated on dabigatran, 2332 (27.5%) on rivaroxaban and 3698 (36.0%) on apixaban. After excluding patients aged ≥80 years, with chronic kidney disease, with a CHA 2 DS 2 -VASc score <2 or a HAS-BLED score >2, a total of 9961 (31.1%) patients initiated on a NOAC received a restricted dosage. Figure 5 illustrates comorbidities and concomitant pharmacotherapy associated with initiation of a restricted dosage of a NOAC compared with the general recommended dosage. Factors associated with initiation of a restricted dosage of one of the NOACs included older age, female gender, a prior myocardial infarction, chronic kidney disease, a prior bleeding event, heart failure, hypertension or treatment with ADP receptor blockers or aspirin.
More patients initiated on a restricted dosage of one of the NOACs had a CHA 2 DS 2 -VASc score ≥1 (Fig. S1 ) or a HAS-BLED score ≥1 (data not shown) compared with those initiated on the recommended standard dosage.
Discussion
In this retrospective registry-based cohort study, we compared characteristics in AF patients initiated on dabigatran, rivaroxaban or apixaban versus VKAs. There were three main findings in this study. First, patients initiated on dabigatran were younger and had lower CHA 2 DS 2 -VASc and HAS-BLED scores, whereas patients initiated on rivaroxaban and apixaban were generally older, than those initiated on VKAs. Furthermore, those initiated on apixaban had higher predicted risk scores than those initiated on VKAs. Secondly, patients with chronic kidney disease, heart failure or a previous myocardial infarction had lower odds of being initiated on dabigatran, rivaroxaban or apixaban compared with a VKA whereas patients who had previously suffered from a stroke had increased odds of being initiated on one of these NOACs. Thirdly, high proportions of patients initiated on one of the NOACs received a restricted dosage compared with the general recommended dosage, and those on a restricted dosage of a NOAC experienced more comorbidities and had a tendency towards higher CHA 2 DS 2 -VASc and HAS-BLED scores.
Age and CHA 2 DS 2 -VASc and HAS-BLED scores
In 2014, we examined the initial usage of NOACs for stroke prophylaxis in AF patients in Denmark from August 2011 until October 2013 and found older age but comparable CHA 2 DS 2 -VASc and HAS-BLED scores in patients initiating one of the NOACs compared with warfarin [11] . In the current study, as well as in a recent Danish study [15] , we found that older age was associated with initiation of rivaroxaban and apixaban, but younger age was associated with initiation of dabigatran compared with VKAs. Furthermore, patients initiated on dabigatran tended to have lower CHA 2 DS 2 -VASc and HAS-BLED scores than patients initiated on VKAs whereas those initiated on apixaban had higher scores. In addition, previous studies have also found that patients initiated on dabigatran were younger than patients treated with warfarin [16, 17] .
Steinberg et al. [16] described the early adoption of dabigatran in AF patients and, in accordance with our findings, they observed that patients initiated
Patients initiating a NOAC / A. Gundlund et al. Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trials comparing dabigatran and apixaban, respectively, with warfarin in AF patients. This may explain the tendency towards prescribing rivaroxaban for older patients and dabigatran for younger patients with lower predicted stroke risk. However, this does not explain the caution shown by clinicians in prescribing apixaban for older patients with high stroke risk scores [8] [9] [10] .
Comorbidities
Danish guidelines for the use of NOACs for stroke prophylaxis in AF patients recommend caution for patients with impaired kidney function, active bleeding or high predicted bleeding risk [19] . In the present study, patients with a previous myocardial infarction or suffering from chronic kidney disease or heart failure (significant only for dabigatran and rivaroxaban) were less likely to be initiated on dabigatran, rivaroxaban or apixaban compared with a VKA whereas patients with a previous stroke had significantly higher odds of being initiated on one of these NOACs. This is in agreement with our previous findings [11] . Baik et al. described patient characteristics and demographics amongst initiators of dabigatran and rivaroxaban compared with warfarin for stroke prophylaxis in AF. Patients who had suffered from stroke, kidney disease, acute myocardial infarction (only for dabigatran) or congestive heart failure had lower odds of being initiated on either dabigatran or rivaroxaban compared with warfarin [20] . Desai et al. [18] found lower odds of initiation of one of the NOACs compared with warfarin in patients who suffered from congestive heart failure, diabetes, stroke, previous bleeding or renal dysfunction. AbuDagga et al. [17] found that warfarin was more likely to be prescribed than dabigatran when patients suffered from impaired renal function or heart failure.
In 2012, an analysis of the RE-LY trial demonstrated a nonsignificant trend towards increased risk of myocardial infarction amongst patients treated with dabigatran versus warfarin [21] . Since then, several studies have investigated whether dabigatran is associated with an increased risk of myocardial infarction compared with warfarin. The results have been conflicting [22] and Caldeira et al. [23] conducted an expert opinion and review in 2016 regarding the coronary risk associated with NOACs. The authors stated that current knowledge did not support the claim of an increased coronary risk amongst patients treated with a NOAC, but acknowledged the need for further evaluation of coronary risk in patients treated with dabigatran. This ongoing discussion may explain our findings with lower odds of initiation of a NOAC compared with a VKA in patients with a previous myocardial infarction.
In the RE-LY trial, the investigators found lower rates of stroke and the same risk of bleeding in patients with AF treated with dabigatran 150 mg twice daily compared with warfarin [8] . In the ROCKET AF trial, rivaroxaban was found to be noninferior to warfarin in stroke prophylaxis in patients with AF, with the same risk of bleeding [9] . In the ARISTOTLE trial, apixaban was found to be superior to warfarin in preventing stroke and caused less bleeding [10] . These clinical trials showed a trend towards better stroke prophylaxis with the same or lower risk of bleeding in AF patients treated with one of the NOACs compared with warfarin. Physicians' treatment preferences may be driven by these trials demonstrating superiority rather than noninferiority and this may explain the higher odds in this study of being initiated on one of the NOACs compared with a VKA amongst AF patients with a history of prior stroke.
Dosage of NOACs
We found that a restricted dosage was used in a high proportion (28-40%) of patients treated with one of the NOACs. Older age, female gender, several comorbidities (including chronic kidney disease) and higher CHA 2 DS 2 -VASc and HAS-BLED scores were associated with initiation of a restricted dosage. In the ARISTOTLE trial, patients with at least two of three characteristics -age ≥80 years, weight ≤60 kg and s-creatinine ≥133 lmol/L -received a restricted dosage of apixaban (4.7% of patients) [10] . In the analysis by Steinberg et al. [16] from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) study, 12% of patients treated with dabigatran received a restricted dosage. In the same study 10% of patients with normal renal function received a reduced dosage. In 2013, Sørensen et al. described the initial use of dabigatran after its approval for stroke prophylaxis in Denmark. They found that those who were initiated on the recommended dosage of dabigatran were in general younger and with fewer comorbidities than those initiated on VKAs or a reduced dosage of dabigatran [24] . In 2016, Hsu et al. [25] found that patients with a CHA 2 DS 2 -VASc score of ≥2 were often not treated with an OAC. The findings of these studies together with ours may indicate caution amongst physicians in prescribing OACs for patients with several comorbidities and therefore a high CHA 2 DS 2 -VASc score. It is likely that many patients with a high CHA 2 DS 2 -VASc score also have a high HAS-BLED score, which may explain the choice of a lower dosage of a NOAC.
Strengths and limitations
Several limitations of this study should be considered. First, this was a registry-based study in which many important factors, such as race, body mass index, smoking, alcohol consumption, labile INR, creatinine clearance, level of education and economic status, were not taken into account. These are factors that may influence the clinical and patient-centered decision-making regarding choice of type of OAC treatment. Secondly, patients with AF who did not receive OAC treatment were excluded from this study, and therefore, whether these patients were appropriately/inappropriately untreated could not be evaluated. Finally, the Danish registries only include diagnosis data from hospital contacts. We excluded a substantial proportion of the study population with a dispensed prescription for an OAC before their diagnosis of AF. It is presumed that these patients were mainly diagnosed with AF by their general practitioner who initiated OAC treatment before referring the patient to an outpatient clinic. This may have led to some degree of selection bias. On the other hand, this study included nationwide high-quality data with complete follow-up and a high positive predictive value of the diagnosis of AF in the Danish registries of 99% [13] .
Conclusions
Patients initiated on dabigatran had lower risk scores for stroke and bleeding than patients initiated on VKAs, whereas those initiated on apixaban had higher predicted risk scores. Fewer patients initiated on dabigatran, rivaroxaban or apixaban had heart failure (only dabigatran and rivaroxaban), chronic kidney disease or a history of a myocardial infarction compared with patients initiated on VKAs, whereas the opposite was observed with regard to stroke. A high proportion of patients initiated on NOACs received a restricted dosage, and this was associated with older age, more comorbidities and high CHA 2 DS 2 -VASc and HAS-BLED scores. The results of this study suggest that there is caution amongst physicians when prescribing NOACs, especially dabigatran, for older and comorbid patients with both high predicted stroke and bleeding risks, and not only for patients with impaired kidney function, older age or high predicted bleeding risk. Studies examining the strategy of physicians regarding choice of NOAC versus VKA, and especially their strategy for restricted dosage of NOACs, will be an important area for future research.
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